ANPCY News and Press, Angle Plc Surrey ADR From 06/14/22

Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation ...

PARTNERSHIP ESTABLISHED WITH A MAJOR UNITED STATES UROLOGY GROUP TO CONDUCT CLINICAL STUDIES IN PROSTATE CANCER AND AS A POTENTIAL ROUTE TO MARKET MidLantic Urology to evaluate the Parsortix system in prostate cancer clinical studies and enable potential sales to Solaris Health extensiv...

Parsortix system harvests intact CTCs for single-cell whole genomic sequencing from frozen and fresh blood samples with the same efficiency Detection of druggable mutations in CTCs enriched from frozen samples may aid treatment decisions in the clinical setting GUILDFORD, UK / ACCES...

Angle (OTC:ANPCF) (OTCQX:ANPCY) said that the U.S. Food and Drug Administration (FDA) cleared Parsortix system for use in harvesting cancer cells from blood of patients with metastatic breast cancer (MBC) for subsequent analysis. The company said it is first ever FDA product clearan...

ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM FDA De Novo product clearance to harvest cancer cells from blood for subsequent analysis offers the prospect of a new era of personalised cancer care Parsortix liquid biopsy system cleared for use in metastatic ...

Research Into the Use of Parsortix-Based CTC Blood Test To Assess Whether Prostate Cancer Patients Require Prostatectomy Surgery Potential for a New Standard of Care in an Area of High Unmet Medical Need GUILDFORD, SURREY / ACCESSWIRE / May 20, 2022 / ANGLE plc ("the Company" ) ...

PARSORTIX SYSTEM RESULTS PUBLISHED AS A POSTER AT LEADING CANCER CONFERENCE AACR 2022 Poster demonstrated use of Parsortix workflow for triple negative breast cancer GUILDFORD, UK / ACCESSWIRE / April 14, 2022 / ANGLE plc ("the Company") (AIM:AGL),(OTCQX:ANPCY), a world-leading liq...

PARSORTIX SYSTEM DEMONSTRATES ABILITY TO ISOLATE CTCs FOR DOWNSTREAM MOLECULAR ANALYSIS, IDENTIFYING KEY DRUG TARGETS INVOLVED IN CANCER METASTASIS World-class research identifies specific genetic steps in the metastatic process, paving the way to test targeted treatment approaches ...

PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS Existing chemotherapies, such as vinorelbine, may selectively target and reduce the metastatic potential of CTCs Detecting a reduction of microtentacles, that ena...

PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple actionable targets Both tumour and CTC samples after pre-surgical chemotherapy show a...